Keyword: Amgen

News

Amgen's Vectibix Given Thumbs Down by European Regulators

21.03.2011 - Amgen said on Friday that European regulators have declined to recommend approval of its drug Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic...

Plant Construction & Process Technology

Pharma Sourcing from India and China

26.01.2011 - India and China are being discovered by more companies as ideal place for pharma sourcing. These two countries continue to be the chosen destinations for a pharmaceutical industry...

News

Amgen To Sell California Drug Plant To Boehringer

19.01.2011 - Amgen, the world's biggest maker of biotechnology drugs, plans to sell its Fremont, Calif., development and manufacturing plant to Germany's Boehringer Ingelheim, the companies...

News

Merck & Co, Parexel Strike Alliance to Develop Biotech Medicines

13.01.2011 - Merck & Co struck an alliance with contract researcher Parexel International to develop copies of biotech medicines, deepening the U.S. drugmaker's investment in so-called...

News

Biosimilar Antibodies: EMA Adopts Guideline

22.11.2010 - European regulators adopted a new guideline on so-called biosimilar antibody drugs on Friday, paving the way for cheaper copies of multi-billion-dollar medicines for cancer and...

News

Biosimilar Antibodies: EU Likely to Be Cautious

17.11.2010 - European regulators are expected to adopt a conservative stance this week when they set rules for allowing copies of antibody drugs, used to fight cancer, rheumatoid arthritis and...

News

Amgen Launches $1.5 billion Two-Part Debt Sale

14.09.2010 - Amgen on Monday launched $1.5 billion of debt in a two-part sale. The offering includes $900 million of 10-year notes expected to yield 77 basis points over comparable U.S...

News

Sanofi's Best Bet Still May Be Smaller Deals

04.08.2010 - Sanofi-Aventis has grabbed the headlines with its $18.4 billion bid for Genzyme, but the French drugmaker may be wiser to stick with smaller, bolt-on acquisitions. Sanofi is trying...